Towards Universal Chemosensory Testing

迈向通用化学感应测试

• 批准号: 10683613
• 负责人: MARK W ALBERS
• 金额: $ 4万
• 依托单位: MONELL CHEMICAL SENSES CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10683613
• 关键词: Affect; Age Years; Ageusia; Anosmia; Area; Attention; COVID-19; COVID-19 pandemic; Caregivers; Chemicals; Child Care; Communication; Communities; Consensus; Diagnosis; Diet and Nutrition; Disease; Economic Burden; Education; Environment; Environmental Hazards; Environmental Risk Factor; Facebook; Family; Fire - disasters; Food; Friends; Functional disorder; Gases; General Population; General Practitioners; Goals; Guidelines; Health; Health Personnel; Health Professional; Healthcare; Hearing; Human; Individual; Industry; Infection; Injury; Institution; Insurance; Intervention; Journals; Language; Lead; Letters; Licensing; Longevity; Mainstreaming; Medical; Methods; Minority; Modeling; Monitor; National Health and Nutrition Examination Survey; National Institute on Deafness and Other Communication Disorders; Neurodegenerative Disorders; Nurses; Nutritional; Olfaction Disorders; Otolaryngologist; Outcome; Paper; Participant; Patients; Peer Review; Persons; Population; Prevalence; Public Health; Publishing; Quality of life; Recommendation; Reporting; Role; Safety; Science; Scientist; Sensory; Sensory Disorders; Signal Transduction; Smell Perception; Smoke; Speed; Strategic Planning; Surveys; Symptoms; Taste Disorders; Taste Perception; Testing; Therapeutic; Time; Translations; Twitter; Update; Vision; Work; academic review; clinical application; cost effective; experience; hazard; improved; interest; live stream; outreach; positive mood; predictive marker; programs; prospective; public education; research clinical testing; screening; screening program; social media; social relationships; specific biomarkers; symposium; virtual; web site

PROJECT SUMMARY The COVID-19 pandemic has brought smell and taste dysfunction to mainstream attention. Despite its role in signaling disease, as well as safety, attachment, and quality of life, the diagnosis of chemosensory disorders is far from accessible for most patients or routinely employed by most health care providers. Aligned with the goals of the 2022-2027 draft of the NIDCD Strategic Plan, we propose a conference to bring together scientists, clinicians, public health officials, patients and all other interested parties to identify opportunities and challenges for implementing routine chemosensory testing nationwide. The organization and execution of the conference result from a collaborative effort of four leaders with diverse backgrounds in the science and clinical application of chemosensory testing who represent institutions with distinct expertise in these areas. Participants in this conference will (i) share state-of-the-art methods in chemosensory testing; (ii) identify benefits and practicalities of chemosensory screening both for individuals and at the population level; (iii) communicate this information to medical associations, health care professionals, academic institutions, governmental agencies, insurance companies, industry, and the general public; and (iv) produce a peer- reviewed, consensus white paper for universal chemosensory testing detailing the rationale and recommendations that emerge from the conference, including a strategy to produce guidelines modeled on other successful campaigns. This in-person conference will include virtual components and childcare assistance, thus enabling the wider participation of diverse groups. We will also make videos of the presentations available online and generate Plain Language materials for the lay public, with both Spanish and English, as outreach content. Together, these activities will advance the use of chemosensory testing in multiple contexts, to speed diagnosis of chemosensory disorders and associated health problems, facilitate therapeutic and supportive interventions for affected individuals, and improve human health and quality of life.

项目摘要 COVID-19大流行使嗅觉和味觉功能障碍成为主流关注点。尽管它在 信号疾病，以及安全性，依恋和生活质量，化学感觉障碍的诊断是 远离大多数患者或大多数卫生保健提供者的常规使用。对准 为了实现2022-2027年NIDCD战略计划草案的目标，我们提议召开一次会议， 科学家、临床医生、公共卫生官员、患者和所有其他相关方，以确定机会， 在全国范围内实施常规化学传感器测试的挑战。的安排和实施 会议是四位在科学和临床领域具有不同背景的领导者共同努力的结果。 化学传感器测试的应用，他们代表在这些领域具有独特专业知识的机构。 本次会议的与会者将（i）分享化学传感测试的最新方法;（ii）识别 对个人和群体水平的化学传感筛选的益处和实用性;（iii） 将此信息传达给医学协会、医疗保健专业人员、学术机构， 政府机构、保险公司、行业和公众;以及（iv）产生同行- 通用化学传感试验的已审查共识白色文件，详细说明了基本原理， 会议提出的建议，包括一项战略， 其他成功的战役。这次面对面的会议将包括虚拟组件和儿童保育 援助，从而使不同群体能够更广泛地参与。我们还将制作 在线提供演示文稿，并为非专业人士提供简单的语言材料，包括西班牙语和 英文，作为外联内容。总之，这些活动将促进化学传感器测试的使用， 多种背景下，以加快诊断化学感觉障碍和相关的健康问题，促进 为受影响的个人提供治疗和支持性干预，并改善人类健康和生活质量。